Status:
UNKNOWN
Study to Assess the Effect of Zinc in Atorvastatin Treated Hyperlipidemic Patients
Lead Sponsor:
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Conditions:
Hyperlipidemias
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
This study was 8 weeks randomized, double-blind, placebo-controlled trial to assess the effect of zinc in Atorvastatin treated hyperlipidemic 92 patients. Participants were assessed at baseline, and 8...
Detailed Description
Hyperlipidemia is a pathological disorder that includes raised concentration of serum cholesterol, LDL and triglycerides (TGs). It is one of the most important triggering factors for the development o...
Eligibility Criteria
Inclusion
- Age: 18 to 75 years
- Sex: both male and female
- Hyperlipidemic patients suffering from ischemic heart disease, diabetes mellitus, hypertension.
- A person can develop hyperlipidemia if they have one or a combination of the following: Diagnostic criteria for dyslipidemic patients (NCEP ATP III guideline) Total Cholesterol \> 240 mg/dl LDL-C \> 100 mg/dl Triglyceride \> 150 mg/dl HDL-C \< 40 mg/dl
Exclusion
- Patients with renal impairment.
- Patient with history of active liver disease (e.g. jaundice, hepatitis, cirrhosis)
- Patients having hypersensitivity to drugs.
- Patients with any systemic diseases or having serious infections or terminal illness (e.g.-tuberculosis, HIV, malignant tumor)
- Pregnant woman
- lactating mother
Key Trial Info
Start Date :
May 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 10 2022
Estimated Enrollment :
92 Patients enrolled
Trial Details
Trial ID
NCT05395143
Start Date
May 1 2021
End Date
July 10 2022
Last Update
May 27 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bangabandhu Sheikh Mujib Medical University
Dhaka, Bangladesh, 1000